Metatatic Breast Cancer: Community Oncology Clinical Debates Part II-Compare emerging evidence regarding use of mTOR and PARP inhibitors for the treatment of patients with Metastatic Breast Cancer. Identify patient population who may benefit from emerging anti-angiogenic therapies for MBC. Develop individualized treatment plans for patients with MBC to optimize clinical outcomes. Provide accurate and appropriate counsel as part of the treatment team
0.75 Free CEUs for Nurses
Expires 11/15/12